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Abstract
The serine protease inhibitors (serpins) are anti-inflammatory proteins that have various functions. By screening a diverse
panel of viruses, we demonstrate that the serpin antithrombin III (ATIII) has a broad-spectrum anti-viral activity for HIV-1,
HCV and HSV. To investigate the mechanism of action in more detail we investigated the HIV-1 inhibition. Using gene-
expression arrays we found that multiple host cell signal transduction pathways were activated by ATIII in HIV-1 infected
cells but not in uninfected controls. Moreover, the signal pathways initiated by ATIII treatment, were more than 200-fold
increased by the use of heparin-activated ATIII. The most up-regulated transcript in HIV-1 infected cells was prostaglandin
synthetase-2 (PTGS2). Furthermore, we found that over-expression of PTGS2 reduced levels of HIV-1 replication in human
PBMC. These findings suggest a central role for serpins in the host innate anti-viral response. Host factors such as PTGS2
elicited by ATIII treatment could be exploited in the development of novel anti-viral interventions.
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Introduction
Serine protease inhibitors (serpins) are elements of the innate
immune system. They are part of the early physiologic response to
viral infection that includes mannose binding lectins, soluble
CD14, defensins, antimicrobial peptides, neutrophils, monocyte/
macrophage and natural killer cells [1]. Serpins comprise a
superfamily of genes that were originally found to regulate
physiologic functions such as blood clotting, complement activa-
tion, programmed cell death, and inflammatory processes [2].
Biochemically, serpins belong to the largest and most diverse
family of protease inhibitors [3]. Over 1000 serpins have been
identified, including 36 human proteins, as well as molecules in
plants, fungi, and bacteria [4,5,6].
Recently, links between serpins and human disease have been
described. The anti-inflammatory activity of ATIII has been
demonstrated in multiple anatomic tissues. In the lung, ATIII has
been shown to inhibit neutrophil infiltration and decrease
microvascular leakage [7]. In the liver, ATIII inhibits hepatic
injury by regulating local prostacyclin levels [8,9]. In the
gastrointestinal tract ATIII attenuates leukocyte adhesion and
rolling [10], and in the skin, ATIII reduces LPS-induced
leukocyte-endothelial cell interaction [11]. Furthermore, ATIII
has been found to influence the pathophysiology of atypical
mycobacterial infection [12], diabetes mellitus [13], and pannic-
ulitis [14].
Serpins have been shown to play both positive and negative
roles in the progression of chronic viral illnesses. Abnormally low
alpha-1 anti-trypsin (AAT) levels in both HIV-1 [15,16], and
HCV infection have been shown to correlate with progressive
disease or the development of liver fibrosis, respectively [17].
Conversely, there is mounting clinical evidence suggesting an
association between increased levels of serpin expression and
reduced incidence of HIV acquisition, or protracted disease
progression [18,19,20].
In the present study, we demonstrated that heparin-activated
ATIII elicit a potent anti-viral response by not only inhibiting
HIV-1 as earlier described [20,21] but also HCV, HSV-1 and
HSV-2. We measured alterations in gene-expression pattern of
HIV-infected PBMC after ATIII treatment to dissect the
underlying mechanisms responsible for anti-viral activity of ATIII.
We found that the PTGS2 protein was an integral component of
an anti-inflammatory cascade. Our findings suggest a central role
for PTGS2 in modulating the host innate response that could be
exploited in the development of novel anti-HIV interventions.
Materials and Methods
Ethics statement
This study was reviewed and approved by the Human Research
Ethics Committee of the Beth Israel Deaconess Medical Center
(BIDMC) and Harvard Medical School (IRB 2006-P-000004).
Written consent was waived since no personal data were collected.
Source of ATIII
Plasma derived human ATIII (Talecris, Durham, NC) with a
biological activity of 6 U/mg was used. ATIII protein was more
than 98% pure, as determined by SDS-PAGE and silver staining,
or by C4 high-pressure liquid chromatography (HPLC). ATIII was
then activated by incubation with heparin as described (referred to
as hep-ATIII). Briefly, ATIII was incubated with equal amounts
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no. 01491) overnight at 37uC to form a non-covalent ATIII-
heparin complex. Unbound heparin was then removed by gel-
filtration with an TSK-gel G2000-SwxI column (Sigma-Aldrich,
St. Louis, MO) as described [21]. Preparations resulted in less than
5% (w/w) free heparin.
Large-scale screen of ATIII antiviral activity
The inhibitory hep-ATIII was determined using standard viral
inhibition assays [22,23,24,25,26] against a panel of human
pathogenic viruses and multiple subtypes that include: HIV-1,
HCV, HSV-1, HSV-2, Measles, VEE, Tacarible Virus, SARS,
Rift Valley Fever (MP-12), RSV A, Rhinovirus, PIV, New Guinea
virus, Adenovirus (65089, Chicago), WNV and Dengue (New
Guinea C) courtesy of the NIH biodefense program (http://www.
niaid-aacf.org/screeningassays.htm). Inhibition of HCV replica-
tion was measured using the HCV OR6 replicon by the
percentage of retained luciferase activity measured after ATIII
treatment against an untreated control [27]. Luciferase activity
was measured with the Renilla Luciferase Assay System (Promega,
Madison, WI) for 1 sec. intervals using the 1420 Multilabel
Counter Victor 3 (PerkinElmer, Waltham, MA).
Briefly, for each specific virus, drug concentrations in 5-fold
increments were used in a virus-specific cell-based assay. From
these data, the 50% inhibitory concentration (IC50), was calculated
using the MacSynergy II Software [28]. Controls for inhibition
experiments included vehicle buffer, bovine serum albumin (up to
30 mM) and a heparin control resembling the hep-ATIII
purification step. Controls never reached more than 25%
inhibition compared to untreated controls. A screen for drug
toxicity was conducted in parallel. The 50% cytotoxic concentra-
tion (CC50) was determined on the basis of Neutral Red and
Trypan blue (Sigma-Aldrich) stain exclusion. To determine if each
compound has sufficient antiviral activity that exceeded its level of
toxicity, a selectivity index (SI) was calculated according to CC50/
IC50. An inhibition that had a SI of 10 or greater was considered
to have useful anti-viral activity.
Signal transduction pathway profiling
Hypaque-gradient purified human PBMC were stimulated for 3
days with 6.25 mg/ml concanavalin A (Con A) and then cultured
in RPMI 1640 (Sigma-Aldrich) supplemented with 10% heat-
inactivated fetal calf serum (FCS, Sigma-Aldrich), 10 mM
HEPES, 2 mM glutamine, 100 U penicillin per ml, 10 mg of
streptomycin per ml, and 50 U of IL-2 per ml (RPMI-50). PBMC
(5610
5 cells/ml) were infected with a 0.01 multiplicity of infection
(MOI) with primary isolate HIV 89.6 in a 96 well format [29] for
2 hours at 37uC. Afterwards, cells were washed twice and
incubated with different amounts of ATIII or hep-ATIII in
RPMI-50. Cells were harvested after 48 hr and total RNA was
recovered using the RNeasy Kit (Qiagen) with a on-column
DNAse digest (Qiagen) according to the manufacturer’s protocol.
Approximately 100 ng RNA was used for cDNA synthesis using
the SuperArray RT
2 First Strand Kit (SABiosciences, Frederick,
MD, cat. no. C-03). cDNA synthesized was used for the RT
2
Profiler PCR Array Human Signal Transduction PathwayFinder
(SABiosciences, cat. no. PAHS-014A). The genes that were
investigated can be found at http://www.sabiosciences.com/
rt_pcr_product/HTML/PAHS-014A.html. Three arrays of three
independent experiments were performed for each treatment
condition. Relative levels of transcription were determined by
using the DCt values for each gene obtained by subtracting the
mean threshold cycle (Ct) of the GAPDH housekeeping gene from
the Ct value of the gene of interest. Average DCt value for 3
experiments was calculated, for each gene of interest, and average
normalized transcription was calculated as follows: 2(-avera-
geDCt)
21. Fold increases of gene transcription, before and after
treatment was calculated by dividing the average normalized
transcription of each gene in the test samples by the corresponding
control. Statistical significance in up- or down-regulation of
transcription was determined by Student t test (2-sample, equal
variance, 2-tailed distribution), comparing the DDCt (DDCt=DCt
treated - DDCt control). Significant differences were identified
when P was less than 0.05.
PBMC transfection and viral HIV-1 inhibition
measurements
PBMC were hypaque-gradient purified and stimulated with
6.25 mg/mL ConA for 3 days. Cells were cultured in RPMI-50.
PBMC (5610
5 cells/ml) were then transfected with the pCMV-
PTGS2 construct (OriGene Technologies Inc.) using the PolyMag
Magnetofection
TMmethod (OZBiosciences, Marseille, France) in
RPMI-50 according to the manufacturer’s protocol. Twenty-four
hours after transfection PBMC were infected with a MOI of 0.01
with HIV 89.6 for 2 hrs, washed extensively and cultured at 37uC
for 48 hrs in RPMI-50. To determine viral inhibition, HIV-1
RNA levels from cell culture supernatants were measured using
the COBAS Ampliprep/COBAS Taqman 48 system (Roche,
Indianapolis, IN) according to manufacturer’s protocol and
compared to controls.
Analysis of protein interactive networks and statistical
analysis
Functional analysis of interacting proteins was determined by
using a commercial System Biology package, Ingenuity Pathways
Analysis (IPA 8.0) (www.ingenuity.com) following the application
directed protocols.
The statistical significance of differences between groups was
determined using the program GraphPad Prism 4.0. A P value of
,0.05 was considered statistically significant. Statistical analysis
was performed by use of the Mann-Whitney test and the DDCt
method.
Western-blot analysis
Cells were homogenized by sonification. The protein concen-
tration of the cell homogenate was determined with the Quick
Start Bradford Dye Reagent (Bio-Rad, Hercules CA). Cellular
homogenate was separated by SDS-PAGE and blotted as
described [24]. Blots were developed as described [30] using a
polyclonal PTGS2 antibody (Cell Signaling Technologies, Inc.,
Danvers, MA).
PTGS2-ELISA
Peripheral blood mononuclear cells were isolated by Ficoll-
Hypaque gradient centrifugation from whole blood of healthy
human donors (Research Blood Components). PBMC were
stimulated with 6.25 mg/mL Con A for 3 days. PBMC were
then cultured in RPMI-50 and subsequently infected with HIV-1
89.6 at a multiplicity of infection of 0.01. Hep-ATIII was added
to infected and uninfected control PBMC at concentrations of
0.09, 0.17 and 0.4 mM. After an additional 48 hours of
incubation, cells were lysed using the CytoBuster Protein
Extraction Reagent (Novagen/EMD Biosciences, Gibbstown,
NJ), and PTGS2 was quantified using the PTGS2-specific ELISA
Kit (EMD Biosciences, Gibbstown, NJ) according to manufac-
turer’s instructions.
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Screen for ATIII-mediated inhibition of a diverse virus
panel
Prior studies by our group have demonstrated the anti-HIV-1
activity of ATIII [20,21]. To determine the potential range of
ATIII-mediated antiviral activity we used a large-scale screen for
inhibitory activity against a diverse panel of 15 human viruses. In
this screen, we identified 3 pathogenic human viruses that were
significantly inhibited by ATIII treatment, including HIV-1
(Table 1). The HIV-1 specific inhibitory activity of ATIII alone,
while significant, required multiple-fold higher levels of ATIII than
its normal 2.4 mM physiologic concentrations. However, the
activation of ATIII with heparin (hep-ATIII) prior to its use in
virus inhibition assays, dramatically increased its HIV-1-specific
antiviral activity (Table 1). Unmodified ATIII had an IC50 for
HIV-1 of 0.2–1 mM which was at least 3-fold higher than that of
hep-ATIII. The difference in inhibitory activity between unmod-
ified and modified ATIII was greater for several other viruses in
the panel. For HCV, heparinization decreased the IC50 5.8-fold.
Unmodified ATIII had no activity against HSV-1 and HSV-2,
whereas hep-ATIII had IC50s of ,6610
26 and 5.3610
23 mM
respectively. Interestingly, the HSV-1 and HSV-2 IC50s were at
least 10-fold lower than the ones for HIV and HCV. Importantly,
hep-ATIII showed a clinically favorable selectivity index of up to
.3000.
HIV-1 induced changes in cellular gene expression
without drug treatment
We sought to elucidate ATIII’s mechanism of action underlying
ATIII viral inhibition using gene expression profiling of well-
characterized cellular signal transduction pathways. We screened
for alterations in gene expression as a result of ATIII or hep-ATIII
treatment in 20 different signal transduction pathways (totaling 84
independent genes) using a RT-PCR-based gene array. We first
investigated the effect of HIV-1 infection alone to establish a
baseline of transcriptional profiles that were associated with early
viral replication. Compared to vehicle treated PBMC, we found
that within 48 hrs of infection, HIV significantly altered the
regulation of 8 genes from 5 signal pathways (Fig. 1). The heat-
shock protein pathway was prominently altered, with heat-shock
protein 90 (HSP90) expression increased to more than 500-fold
over basal levels (P=0.02). Interestingly, the expression levels of 2
genes from the NF-kB pathway were also altered; TRAF family
member-associated NFkB activator (TANK) was increased 50-
fold, whereas the expression of the anti-apoptotic baculo-viral IAP
repeat-containing-2 gene (BIRC2) diminished approximately 10-
fold (P=0.04). We also found that genes fibronectin 1 (FN1)
(P=0.03) and myelocytomatoxis viral oncogene homolog (Myc)
(P=0.03) of the phosphoinositide-3 (PI3) kinase/AKT pathway
were down regulated 10-fold (Fig. 1). Moreover, expression levels
of the two cyclin-dependent kinase inhibitors, CDKN2A and
CDKN2B, of the transforming growth factor- (TGF) pathway
were up to 10-fold decreased with P of 0.02 and 0.03, respectively.
Finally, we found an up to 5-fold (P=0.002) down-regulation of
the expression of the tumor suppressor and DNA repair gene
breast cancer type 1 susceptibility protein (BRCA1) (Fig. 1).
ATIII-induced gene expression changes in uninfected
PBMC
We also tested the effect of ATIII alone on cellular gene
expression in human PBMC to determine transcriptional changes
affected by ATIII in the absence of HIV infection. We found that
compared to vehicle treated controls, the levels of transcription of
both interleukin 2 (IL-2) and colony stimulating factor-2 (CSF2),
were altered in a dose-dependent manner up to more than 7-
(P=0.02) and 5-fold (P=0.0002), respectively. Additionally,
BRCA1 expression was more than 3-fold (P=0.01) decreased
(Fig. 2).
ATIII-induced alterations in gene expression in HIV-1
infected PBMC
We evaluated the effect of 6.8, 34 and 68 mM ATIII on gene
expressioninselectedsignaltransductionpathwaysinHIV-1-infected
PBMC. We identified several genes whose expression was affected by
ATIII treatment during HIV infection when compared to the vehicle
treated controls, but which were not perturbed by HIV-1 replication
in the absence of ATIII (Fig. 1) or by ATIII treatment of uninfected
cells (Fig. 2).Wefound that when compared to the untreated control
the transcription of IL-8 and IL-1a were increased both more than
75-fold (P=0.0008 and P=0.0009, respectively); chemokine C-C
motif ligand 20 (CCL20) was more than 17-fold increased (P=0.02).
In contrast, platelet/endothelial cell adhesion molecule (PECAM1,
CD31 antigen) was 7-fold (P=0.002) and IL-2 was more than 3-fold
down-regulated (P=0.049) at the highest ATIII concentration used
(Fig. 3A and B).
Interestingly, PTGS2 was the most dramatically up-regulated of
all genes investigated. When ATIII was added at 2.5-fold its
physiological concentration, 6.8 mM, PTGS2 gene expression
levels increased dramatically to 110-fold (P=0.0001) over baseline
levels. At the highest concentration of ATIII tested, PTGS2
transcription was increased to over 315-fold (P,0.0001) of control
expression levels (Fig. 3A). Other signal transduction pathways
affected included the p53 pathway with the Fas receptor, up to 5-
fold increased (P=0.02), and the PI3 kinase/AKT pathway with
matrix metalloproteinase 7 (MMP7) and hexokinase 2 (HK2), both
up to over 5-fold up-regulated (P=0.001 and 0.047, respectively)
(Fig. 3A).
Heparin activated ATIII-induced host genes in HIV-1
infected PBMC
Non-activated ATIII is only a weak inhibitor of HIV-1
replication on its own. Multiple magnitudes of its 2.4 mM
physiological concentrations are needed to achieve high viral
(.90%) inhibition. Heparin activation of ATIII potently increases
Table 1. IC50 of ATIII and hep-ATIII.
Serpin Virus
a IC50 (mM)
ATIII HIV
b 0.2–1
HCV
c 43
HSV-1 Not active
HSV-2 Not active
Hep-ATIII HIV 0.06
HCV 7.3
HSV-1 ,6610
-6
HSV-2 5.3610
-3
aVirus inhibition measured for the following viruses: HIV-1, HSV-1, HSV-2. No
inhibition was observed for Measles VEE, Tacarible Virus, SARS, Rift Valley Fever
(MP-12), RSV A, Rhinovirus, PIV, New Guinea virus, Adenovirus (65089,
Chicago), WNV, Dengue (New Guinea C), and HCV.
bHIV-1IIIB with H9 T cell line was used.
cHCV replicon with full-length hepatitis C virus genome, strain O, was used.
doi:10.1371/journal.pone.0018589.t001
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also has an effect on genes altered by ATIII during acute infection.
We hypothesized that since anti-viral activity is increased by hep-
ATIII, genes responsible for its viral inhibition might also be
increased. Based on our data of the relative viral inhibitory
capacities of ATIII versus hep-ATIII, we determined that we
could use 200-fold less hep-ATIII (by concentration) as compared
to ATIII alone to elicit equivalent changes in gene transcription
and subsequent viral inhibition.
Using 0.4 mM of hep-ATIII, we found the same genes up-
regulated PTGS2 (P=0.0007), IL-8 (P,0.0001), IL-1a
(P,0.0001) and CCL20 (P,0.0001), or down-regulated PECAM1
(P=0.0013) (Fig. 4A and 4B) as with a much higher dose of non-
activated ATIII treatment. Overall, this confirmed our hypothesis
that the enhanced viral inhibition mediated by hep-ATIII is
largely achieved by similar transcriptional regulation as was
effected by non-activated ATIII. Again, hep-ATIII activated
PTGS2 potently, more than 380-fold at 0.4 mM when compared
to untreated infected controls.
Interestingly, several genes did exhibit different transcriptional
changes with hep-ATIII treatment compared to non-activated
ATIII. Specifically, CDKN2B gene activity (P=0.0005 at 0.4 mM)
was increased (Fig. 4A), whereas FN1 (P=0.005 at 0.4 mM) and
chemokine (C-X-C motif) ligand 9 (CXCL9) (P=0.0001 at
0.4 mM) were transcriptionally down-regulated (Fig. 4B). We
attribute these differences to the increased biological activity of the
heparin-activated ATIII derivative.
Network analysis of ATIII-induced interactomes during
HIV-1 replication
To gain further insight into the mechanism of action of hep-
ATIII in reducing HIV replication, we performed a biologic
network analysis. This analysis method complements data
generated from our gene arrays by facilitating the recognition
hierarchical gene clusters that intersect with HIV replication.
Using this method, we analyzed the effect of HIV-1 infection on
PBMC in the absence of ATIII treatment. We found the NF-kB
node of proteins scored significantly during HIV infection,
Figure 1. Effect of acute HIV infection on PBMC gene expression. Gene expression profiling of PBMC acutely infected with HIV-1. For signal
transduction gene analysis, 10
5 PBMC were infected with a 0.01 MOI of the primary isolate HIV-1 (HIV 89.6), for 2 h at 37uC. Total RNA was purified
two days after infection. A RT-PCR expression array was performed and gene expression of 84 genes from 20 different signal transduction pathways
was analyzed. Genes with significant changes in gene expression (p,0.05, n=3) compared to uninfected vehicle treated controls are shown.
Significance was calculated using the DDCt method for three independent experiments.
doi:10.1371/journal.pone.0018589.g001
Figure 2. Effect of ATIII on gene expression in uninfected
PBMC. Gene-regulation of uninfected PBMC treated with different
doses of ATIII, each dose compared to an uninfected, ATIII untreated
vehicle control. For signal transduction gene analysis, 10
5 PBMC were
infected with a 0.01 MOI of primary isolate HIV-1 (HIV 89.6) for 2 h at
37uC. Cells were washed and treated with 6.8, 34 and 68 mM ATIII for
48 h. Total RNA was purified and a RT-PCR expression array was
performed. The expression of 84 genes from 20 different signal
transduction pathways was analyzed. Genes with significant changes in
gene expression (p,0.05, n=3) compared to controls are shown.
Significance was calculated using the DDCt method for three
independent experiments.
doi:10.1371/journal.pone.0018589.g002
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RNA transcription. We found that 6 genes were significantly
altered, and all intersect the NF-kB node. Three of these genes
baculoviral IAP repeat containing 2 (Birc2), Myc and FN1 are
strongly down-regulated, and CDKN2A, CDKN2B and BRAC1
are moderately down-regulated during acute HIV-1 infection
(Fig. 5A). The highest increase in transcription was observed with
HSP90-AA2, connected with the extracellular signal-regulated
kinases (ERK) and ERK1/2 node during HIV infection.
We then examined the effect of hep-ATIII treatment in HIV
infected cells. Using the same analysis method, we found a
network with several genes and gene clusters that changed more
than 2-fold during 48 h of hep-ATIII treatment. We found that
most genes are connected with the NF-kB nodule (Fig. 5B): Highly
activated was the cytokine IL-1, moderately altered are ICAM1,
CDKN2B, TNF, BIRC3, Fas, Tank, BCL2A1, chemokine (C-C
motif) ligand 2 (CCL2) and CCL20. There were also genes down-
regulated dependent on the NF-kB nodule: CXCL9 and vascular
cell adhesion molecule 1 (VCAM1) were significantly down-
regulated (Fig. 5B). Other nodules in the same network were IL1,
Tnf and the Nf-kB1-RefA dimer.
There is also another network activated by hep-ATIII treatment
during HIV infection (Fig. 5C) which includes proteins dependent
on the activator protein (Ap1) transcription factor, including
Figure 3. Effect of ATIII on gene expression in acutely HIV infected PBMC. (A) Gene up-regulation of acutely infected PBMC after treatment
with different doses of ATIII, each dose compared to infected untreated control. (B) Gene down-regulation of acutely infected PBMC after treatment
with different doses of ATIII, each dose compared to an infected untreated control. For signal transduction gene analysis, 10
5 PBMC were infected
with a 0.01 MOI of primary isolate HIV-1 (HIV 89.6) for 2 h at 37uC. Cells were washed and treated with 6.8, 34 and 68 mM ATIII for 48 h. Total RNA was
purified and a RT-PCR expression array was performed. The gene expression levels from 20 different signal transduction pathways were analyzed.
Genes with significant changes in gene expression (p,0.05, n=3) compared to controls are shown. Significance was calculated using the DDCt
method for three independent experiments.
doi:10.1371/journal.pone.0018589.g003
Figure 4. Effect of heparin activated ATIII (hep-ATIII) on gene expression in acutely HIV infected PBMC. (A) Gene up-regulation of
acutely infected PBMC after treatment with different doses of hep-ATIII, each dose compared to infected hep-ATIII untreated vehicle control. (B) Gene
down-regulation of acutely infected PBMC after treatment with different doses of hep-ATIII, each dose compared to infected hep-ATIII untreated
vehicle control. For signal transduction gene analysis, 10
5 PBMC were infected with a 0.01 MOI of primary isolate HIV-1 (HIV 89.6) for 2 hrs at 37uC.
Cells were washed and treated with 0.09, 0.17 and 0.4 mM hep-ATIII for 48 h. Total RNA was purified and a RT-PCR expression array was performed.
The expression levels of genes of 20 different signal transduction pathways (84 genes) were analyzed. Genes with significant changes in gene
expression (p,0.05, n=3) compared to controls are show. Significance was calculated using the DDCt method for three independent experiments.
doi:10.1371/journal.pone.0018589.g004
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this network is Vegf which regulates PTGS2. Moreover, several of
these proteins intersect with the insulin node that regulates the
anti-inflammatory immune responses of other serpins [31].
Over-expression of PTGS2 affects HIV-1 replication
In order to assess the potential of PTGS2 to independently
impact HIV-1 infection, we transiently expressed the human
PTGS2 protein in human PBMC cells. We observed from
Figure 5. Interactive network analysis in acutely HIV-1 infected PBMC. (A) Effect of HIV-infection on gene expression in PBMC without hep-
ATIII treatment. (B) The highest scored primary network activated by hep-ATIII in HIV-1 infected PBMC. (C) The secondary overlapping network
activated by hep-ATIII in HIV-1 infected PBMC. Pathway analysis of significant up-regulated (red and down-regulated (green) genes in HIV-1 infected
PBMC using Ingenuity Pathways Analysis Software. Significance was calculated using the DDCt method for three independent experiments.
doi:10.1371/journal.pone.0018589.g005
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expression could be reproducibly achieved. When PTGS2-
transfected cells were incubated with HIV-1, a 50% reduction of
HIV-1 replication (HIV RNA copies/ml) was observed after
48 hrs as compared to controls transfected with an empty DNA
vector (Fig. 6A and B). We also conducted experiments to
measure the kinetics of PTGS2 during viral infection at various
doses of ATIII. We found that PTGS2 expression increased in a
dose-dependent manner at 48 hours, and this was specific for
HIV-infected cells (Fig. 6C).
In summary our results demonstrate (1) that PTGS2 is potently
activated by ATIII in virus-infected cells, (2) that PTGS2 over-
expression can significantly reduce virus production in HIV-
susceptible cells in vitro, and (3) that PTGS2 might act as an HIV
inhibitory host cell factor by direct or indirect interference with
factors required for productive virus replication.
Discussion
Serpins have a plethora of functions [7,8,9,10,11,12,13,14]. It
was recently demonstrated that serpins are potential inhibitors of
HIV-1 replication in the blood and mucosa [16]: (1) Early during
HIV infection, serpin levels in the blood increase rapidly to levels
in the range of their in vitro inhibitory activity [32]; (2) The serpin,
secretory leukocyte inhibitor (SLPI), has been described as an
important HIV-1 inhibitory factor in saliva [33]; (3) serpins are
highly expressed in the cervical fluids of exposed but uninfected
sex workers [19], and (4) serpins are highly expressed in HIV long-
term non-progressors [20,24].
We, thus, initiated an investigation of the antiviral properties of
the serpin ATIII. We demonstrated that ATIII can inhibit a
variety of disparate viruses: HIV-1, HCV, HSV-1 and HSV-2. We
subsequently focused our investigation on identifying gene-
Figure 6. Inhibition of HIV replication by PTGS2. (A) Viral replication measured in RNA copy number per ml of mock-transfected (empty vector)
and pCMV-PTGS2-transfected (PTGS2) PBMC. (B) Protein expression of Western-blot of 20 mg lysate protein of mock-transfected (lane 1) or PTGS2-
transfected PBMC (lane 2). PBMC were transiently transfected with plasmid DNA. After 2 days cells were infected with a 0.01 MOI of the HIV-1 primary
isolate (HIV 89.6) for 2 hrs at 37uC. Cells were washed and supernatant was collected after 48 hr. HIV-1 RNA levels were measured using the COBAS
Ampliprep/COBAS Taqman 48 system for three independent experiments. For the Western analysis, transfected Jurkat cellular homogenates (20 mg/
lane) were separated by SDS-PAGE. Target proteins were identified by Western analysis using polyclonal antibody generated against the PTGS2
protein. Representative data of three independent experiments are shown. (C) PBMC were infected with HIV-1 primary isolate (HIV 89.6) at a MOI of
0.01. Hep-ATIII was added at concentrations of 0.09, 0.17 and 0.4 mM. After 48 hours, PTGS2 was quantified using the PTGS2-specific ELISA.
doi:10.1371/journal.pone.0018589.g006
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treatment of HIV-infected cells in an attempt to identify host-cell
factors which might act down-stream of ATIII. We decided to
focus our study on HIV-1 under the assumption that the
mechanism of action of ATIII might not be identical for different
viruses.
To begin to understand the anti-HIV mechanism of action of
ATIII, we used gene-expression arrays and protein network
analysis to probe the signaling pathways activated by ATIII. This
gene expression analysis indicated that the mechanism of serpin-
mediated viral inhibition is multifactorial, involving a number of
prominent signal transduction cascades. Furthermore, our net-
work analysis has indicated that the proteins involved in reducing
HIV replication may derive from multiple intersecting signaling
pathways, although there is likely to be some level of redundancy
in these regulatory and signaling cascades.
We found that ATIII induced significantly more comprehensive
transcriptional changes in virus-infected cells than in uninfected
cells. This apparent specificity in the mechanism of ATIII may be
used to clinical advantage, as it should minimize cytotoxicity in
bystander cells and thus reduce the possibility of side effects of
ATIII treatment.
Among the transcripts regulated by ATIII, PTGS2 was
distinguished as being most potently up-regulated by ATIII. To
determine if PTGS2 activation alone might be sufficient to confer
the observed anti-viral effect of ATIII, we over-expressed PTGS2
in infected cells. We found that the over-expression of PTGS2
reduced the replication of HIV in primary cells, although not to
the extent observed with ATIII. The reason for this might be that
we never achieved the increase of expression using the PTGS2-
DNA plasmid as seen for the activation of PTGS2 expression by
hep-ATIII. Furthermore, it is possible that there are additional
inhibitory factors involved.
It has been previously demonstrated that ATIII, at least in part,
exerts its anti-inflammatory effect by induction of prostacyclins, a
family of eicosanoids acting in autocrine and paracrine pathways
[2]. PTSG2 enzymatically synthesizes the eicosanoid prostaglan-
din H2. Another eicosanoid, prostaglandin A1 has also been
shown to inhibit HSV 1 and 2 replication [34]. It is therefore
possible that the observed inhibition of different viruses by ATIII is
the result of downstream synthesis of eicosanoids mediated by
PTGS2.
PTGS2 is known to down-regulate NF-kB mediated transcrip-
tion, which is a critical element in HIV-1 replication [2]. Efficient
HIV-1 gene expression depends on NF-kB to activate viral
transcription. The promoter-proximal (enhancer) region of the
HIV-1 long terminal repeat (LTR) contains two adjacent NF-kB
binding sites (2109 to 279) that play a central role in mediating
inducible HIV-1 replication. In addition to HIV-1, NF-kBi s
activated by several families of viruses, including HTLV-1,
hepatitis B virus (HBV), hepatitis C virus (HCV), EBV and
influenza virus. This activation serves to maximize virus genome
production, abort the apoptosis of infected cells, and forestall
immune responses to the invading pathogen.
We propose that ATIII inhibits HIV-1 replication through
activation of PTGS2, which then modulates the NF-kB pathway.
Our network data indicate that in addition to the NF-kB
transcriptional network, the TNF transcriptional network may
also be affected by PTGS2. The importance of the TNF network
in the function of serpins has previously been described [31]. Our
studies do not exclude other factors aside from PTGS2 being
involved in ATIII-mediated virus inhibition. However, both our
gene array and network analysis suggest a role for pharmacologic
stimulation of PTGS2 in HIV-1 target cells as a means of
interdicting the NF-kB cascade and blocking viral replication.
Further investigation into the mechanism of action of PTGS2 and
other proteins regulated by ATIII therapy might provide new
insights into the development of anti-viral therapeutics or
prophylactic agents.
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